Audentes Prices $75M IPO As Gene Therapy Eyes First U.S. Approval
Xconomy
JULY 20, 2016
The $75 million raise will help Audentes fund clinical work it’s doing on rare diseases such as X-Linked myotubular myopathy, Crigler-Najjar Syndrome, and Pompe disease. Gene therapy’s multi-decade roller-coaster ride has been well documented, in Xconomy and elsewhere. million in equity financing since its 2012 inception, and had $80.3
Let's personalize your content